Armata Pharmaceuticals (ARMP) Expected to Announce Quarterly Earnings on Thursday

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) will likely be issuing its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $0.74 million for the quarter.

Armata Pharmaceuticals Trading Down 0.8%

Shares of NYSEAMERICAN ARMP opened at $9.61 on Wednesday. The stock has a market cap of $349.90 million, a P/E ratio of -5.93 and a beta of 1.30. Armata Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $16.34. The stock has a 50 day moving average of $8.45 and a two-hundred day moving average of $6.17.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ARMP shares. HC Wainwright upped their price target on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. JonesTrading assumed coverage on shares of Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at $108,000. Millennium Management LLC acquired a new stake in shares of Armata Pharmaceuticals in the 4th quarter worth $164,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter valued at about $177,000. Goldman Sachs Group Inc. purchased a new stake in shares of Armata Pharmaceuticals in the fourth quarter valued at about $284,000. Finally, State Street Corp increased its stake in shares of Armata Pharmaceuticals by 26.1% during the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after acquiring an additional 10,500 shares during the period. 3.57% of the stock is currently owned by hedge funds and other institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.